Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Claudin 2/CLDN2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLDN2 Extracellular Loop (ECL1-ECL2) Recombinant Protein HEK293 Expressed (Native Glycosylation), Sequence Verified, Purity >95%, Endotoxin Controlled. Ideal for ELISA and SPR screening. |
View CLDN2 Products |
| Gene Delivery | CLDN2 Lentivirus Premade Particles Full-length human CLDN2 ORF. Designed for stable cell line generation to preserve native 4-transmembrane conformation in flow cytometry and functional assays. |
View CLDN2 Products |
| Benchmark Ab | Anti-CLDN2 Recombinant Antibody Recombinant positive control derived from benchmark research clones. Sequence verified. |
View CLDN2 Products |
| Validator | CLDN2 siRNA Set Target-specific siRNA pool for target knockdown validation in cell-based assays. |
View CLDN2 Products |
| Related Target A | CLDN1 Critical family member for selectivity counter-screening to avoid off-target toxicity. |
View CLDN1 Products |
| Related Target B | CLDN18.2 Validated oncology target in the Claudin family; useful for comparative therapeutic indexing. |
View CLDN18.2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preservation of 4-Transmembrane Conformation | Lentivirus-mediated stable cell line expression avoids the misfolding and instability issues of detergent-solubilized proteins. |
| Selectivity Against Homologous Claudins | Cross-reactivity panels featuring CLDN1, CLDN3, and CLDN4 recombinant loop proteins are strictly quality-controlled via theoretical MW and sequence verification. |
| Lack of Validated Positives | Recombinant Benchmark Biosimilar Antibodies are included to establish reliable positive baselines. |
| False Positive Knockdown Signals | Sequence-verified siRNA sets enable direct orthologous verification of target-specific phenotypic changes. |
Live Claudin 2/CLDN2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Claudin 2 (CLDN2) is emerging as a highly promising frontier in both oncology and inflammatory bowel diseases (IBD). Unlike CLDN18.2, which is strictly associated with gastric and pancreatic cancers, CLDN2 is a "leaky" tight junction protein. Its overexpression in colorectal cancer (CRC) correlates with tumor progression, epithelial-mesenchymal transition (EMT), and liver metastasis. Concurrently, in inflammatory conditions like ulcerative colitis, CLDN2 upregulation compromises intestinal barrier integrity.
The race for CLDN2 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to antibody-drug conjugates (ADCs) and bispecific antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective epitope regions on the extracellular loops to avoid cross-reactivity with closely related family members like CLDN1.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Oncology Biotechs, Academic Consortia | Colorectal Cancer, Gastric Cancer | Internalization Assay (Requires native-conformation CLDN2 expressing target cells generated via Lentivirus) |
| Bispecific Antibodies / T-Cell Engagers | Immunotherapy Pioneers | Solid Tumors, Metastatic CRC | Heterodimer Validation & Selectivity (Requires high-purity CLDN1/CLDN2/CLDN4 panel proteins) |
| Small Molecule Blockers | Gastrointestinal Specialist Pharma | Inflammatory Bowel Disease (IBD) | Barrier Function & Pore Blockade Assays (Requires stable cell lines with robust TEER values) |